RTSN stock news · Retension Pharmaceuticals, Inc.
Get alerts for RTSN
Follow Retension Pharmaceuticals, Inc. (RTSN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RTSNFree on the App Store and Google Play, or on the web.
Retension Pharmaceuticals shared its third quarter results and updates on its RTN-001 clinical trial.
NeutralRetension's October IPO raised $45.1 million after costs to support its trial. It also issued 4.3 million shares, and trial results remain pending, leaving the outlook unchanged.